Habte A.YimerMD

Oncology • Tyler, TX

Gastrointestinal Cancer, Hematologic Oncology, Thoracic Cancer

Physician

Join to view full profile

Dr. Yimer is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Yimer's full profile

Already have an account?

Office
501 Saunders Ave
Ste 200
Tyler, TX 75702
Phone+1 903-579-9800

Fax+1 903-592-5988

Education & Training

Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 2005 - 2008
University of Illinois College of Medicine at ChicagoResidency, Internal Medicine, 2002 - 2005
Gondar College of Medical SciencesClass of 1998

Certifications & Licensure

TX State Medical License 2008 - 2026
MN State Medical License 2005 - 2008
IL State Medical License 2002 - 2005
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology
National Board of Physicians and Surgeons Hematology
National Board of Physicians and Surgeons Internal Medicine
National Board of Physicians and Surgeons Medical Oncology

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Clinical Trials

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma Start of enrollment: 2020 Sep 03
Recruiting
Phase 2, Phase 3
A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM) Start of enrollment: 2021 Apr 20
Terminated
Phase 1, Phase 2
Roles: Principal Investigator
Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications Start of enrollment: 2016 Jan 01
Active, not recruiting
Phase 1, Phase 2
Roles: Principal Investigator, Contact
A Study of TAK-981 Given With Rituximab in Adults With Relapsed or Refractory CD20-Positive Non-Hodgkin Lymphoma Start of enrollment: 2019 Oct 15
Terminated
Phase 1, Phase 2
Roles: Principal Investigator
A Study to Evaluate Safety and Efficacy of Selinexor Versus Treatment of Physician's Choice in Participants With Previously Treated Myelofibrosis Start of enrollment: 2021 Mar 17
Active, not recruiting
Phase 2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

1 citations
OUTREACH: phase 2 study of lisocabtagene maraleucel as outpatient or inpatient treatment at community sites for R/R LBCL.
Yuliya Linhares, Cesar O Freytes, Mohamad Cherry, Carlos Bachier, Michael Maris
Blood Advances. 2024-12-10
Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine for Advanced-Stage Classical Hodgkin Lymphoma.
Hun Ju Lee, Rod Ramchandren, Judah Friedman, Jason M Melear, Ian W Flinn
Blood. 2024-12-02
Sustained Benefit of Zanubrutinib vs Ibrutinib in Patients With R/R CLL/SLL: Final Comparative Analysis of ALPINE.
Jennifer R Brown, Barbara Eichhorst, Nicole Lamanna, Susan M O'Brien M.D, Constantine S Tam
Blood. 2024-09-24

Abstracts/Posters

Improvements in Health-Related Quality of Life and Symptoms in Patients with Previously Untreated Chronic Lymphocytic Leukemia: Final Results from the Phase II GIBB St...
Habte A Yimer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Professional Memberships

American Society of Clinical Oncology - ASCO
Member
Texas Medical Association - TMA
Member